Showing results (381-390 of 418) with videos related to

Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology|March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialSandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialFederica Morano, Alessandra Raimondi, Filippo Pagani, et al.
Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.
BMJ Oncology|June 23, 2025
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, et al.
Cancers|July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY StudyAlessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.
Therapeutic Advances in Medical Oncology|June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access programOliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
Pageof 42